Genomenon Acquires Boston Genetics to Accelerate Human Genome Care

Boston Genomenon and Genetics

“This acquisition builds on our success and puts us at the forefront of the race to cure the entire human genome, bringing unprecedented genomic insights to clinical diagnostics, newborn sequencing and drug development programs. – Mike Klein, CEO

Genomenon Inc., a leader in genomics intelligence, today announced that it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for technology-enabled genomic knowledge and scientific expertise with Boston Genetics’ robust team of genetic scientists, Genomenon is now in the leading position to be the first company to cure the entire human genome. The insights through this cure, starting with the clinical exome, will be invaluable in Genomenons’ mission to save and improve lives by making genomic information actionable.

The team’s expanded size and genomics expertise immediately allow Genomenon to offer even greater support to its pharmaceutical and clinical diagnostic customers, as it helps both groups understand the genomic drivers of genetic diseases and oncology. Additionally, the acquisition creates a genomics data services arm for Genomenon, enabling the company to provide cost-effective variant curation team extensions for genetic testing labs to accelerate turnaround times.

Genomenon CEO Mike Klein explained, “Genomenon has always been unique in our approach of combining genetic expertise with our AI-powered genomics engine, Mastermind, which has 100x more genomic evidence and 50x more more variations than any other resource. He continued: We have been working with Boston Genetics for more than three years and have been consistently impressed with the quality of the team’s experience and work. This acquisition builds on our success and puts us at the forefront of the race to cure the entire human genome, bringing unprecedented actionable genomic insights to clinical diagnostics, newborn sequencing, and drug development programs.

Boston Genetics co-founder and CEO Arslan Berbic will join the Genomenon team as vice president of business development, services platform. He commented, “I’m proud of the company my team and I have built with Boston Genetics and I’m thrilled to have him now as part of Genomenon to further enhance the company’s mission to curate the genome.” As a member of the Genomenon team, I am excited as we work to expand our variant curation and interpretation services to our client base by leveraging the Genomenons AI curation engine with expert review from the Boston Genetics team.

The acquisition, effective immediately, adds more than 75 highly skilled genetic scientists to the Genomenon team, doubling the size of the company. Boston Genetics’ current customers include a number of leading genetic testing laboratories in the United States who will now have access to Genomenons AI-powered curation engine and services platform.

About Genomenon

Genomenon is a genomic intelligence company dedicated to improving the quality of life of genetic diseases and cancer patients by making genomic information actionable. Combining the power of artificial intelligence with the precision of genomic expertise, the company provides pharmaceutical companies and the clinical diagnostic community with empirical genomic insights and evidence that support the development of new therapies and expedite diagnostic evaluations and treatment recommendations.

For more information, visit Genomenon.com.

About Boston Genetics:

Boston Genetics was founded in 2019 and is headquartered in Cambridge, MA with offices throughout Bosnia as well. Its genomic interpretation services specialize in germline and somatic care according to ACMG/AMP clinical guidelines. Curators have experience working with bioinformatics, ClinGen, and medical teams and are designed to augment client variant curation teams.

For more information, visit Bostongen.com.

Share the article on social media or email:

#Genomenon #Acquires #Boston #Genetics #Accelerate #Human #Genome #Care
Image Source : www.prweb.com

Leave a Comment